<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04924114</url>
  </required_header>
  <id_info>
    <org_study_id>6194-002</org_study_id>
    <secondary_id>PT101-201</secondary_id>
    <secondary_id>2021-000093-28</secondary_id>
    <nct_id>NCT04924114</nct_id>
  </id_info>
  <brief_title>A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)</brief_title>
  <official_title>A Phase 1b, Randomized, Adaptive, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of PT101 in Subjects With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics,&#xD;
      pharmacodynamics and immunogenicity of MK-6194 in participants with active UC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2021</start_date>
  <completion_date type="Anticipated">November 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 87 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Discontinuing Study Treatment Due to an AE</measure>
    <time_frame>Up to approximately 57 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of MK-6194</measure>
    <time_frame>Pre-dose on Days 1, 29, and 57; 12 hours post-dose (±1 hour), 24 or 48 hours post-dose (±1 hour), and optionally 120 hours post-dose (±2 hours) on Days 1 and 57. Non-dose day samples on Days 9, 14, 22, 37, 42, 50, 65, 70 and 85.</time_frame>
    <description>Cmax is defined as the maximum concentration of MK-6194 observed in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Cmax (Tmax) of MK-6194</measure>
    <time_frame>Pre-dose on Days 1, 29, and 57; 12 hours post-dose (±1 hour), 24 or 48 hours post-dose (±1 hour), and optionally 120 hours post-dose (±2 hours) on Days 1 and 57. Non-dose day samples on Days 9, 14, 22, 37, 42, 50, 65, 70 and 85.</time_frame>
    <description>Tmax is defined as the time of maximum concentration of MK-6194 observed in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t)</measure>
    <time_frame>Pre-dose on Days 1, 29, and 57; 12 hours post-dose (±1 hour), 24 or 48 hours post-dose (±1 hour), and optionally 120 hours post-dose (±2 hours) on Days 1 and 57. Non-dose day samples on Days 9, 14, 22, 37, 42, 50, 65, 70 and 85.</time_frame>
    <description>AUC0-t is defined as the area under concentration-time curve from 0 to last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Concentration (Cmin) of MK-6194</measure>
    <time_frame>Pre-dose on Days 1, 29, and 57; 12 hours post-dose (±1 hour), 24 or 48 hours post-dose (±1 hour), and optionally 120 hours post-dose (±2 hours) on Days 1 and 57. Non-dose day samples on Days 9, 14, 22, 37, 42, 50, 65, 70 and 85.</time_frame>
    <description>Cmin is defined as the minimum concentration of MK-6194 observed in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time 0 to Infinity (AUC0-inf) of MK-6194</measure>
    <time_frame>Pre-dose on Days 1, 29, and 57; 12 hours post-dose (±1 hour), 24 or 48 hours post-dose (±1 hour), and optionally 120 hours post-dose (±2 hours) on Days 1 and 57. Non-dose day samples on Days 9, 14, 22, 37, 42, 50, 65, 70 and 85.</time_frame>
    <description>AUC0-inf is a measure of the total amount of MK-6194 in the plasma from time zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Half-life (t1/2) of MK-6194</measure>
    <time_frame>Pre-dose on Days 1, 29, and 57; 12 hours post-dose (±1 hour), 24 or 48 hours post-dose (±1 hour), and optionally 120 hours post-dose (±2 hours) on Days 1 and 57. Non-dose day samples on Days 9, 14, 22, 37, 42, 50, 65, 70 and 85.</time_frame>
    <description>t1/2 is defined as the time required for the plasma concentration of MK-6194 to decrease by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) of MK-6194</measure>
    <time_frame>Pre-dose on Days 1, 29, and 57; 12 hours post-dose (±1 hour), 24 or 48 hours post-dose (±1 hour), and optionally 120 hours post-dose (±2 hours) on Days 1 and 57. Non-dose day samples on Days 9, 14, 22, 37, 42, 50, 65, 70 and 85.</time_frame>
    <description>CL/F is defined as the apparent clearance of MK-6194 observed in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F) of MK-6194</measure>
    <time_frame>Pre-dose on Days 1, 29, and 57; 12 hours post-dose (±1 hour), 24 or 48 hours post-dose (±1 hour), and optionally 120 hours post-dose (±2 hours) on Days 1 and 57. Non-dose day samples on Days 9, 14, 22, 37, 42, 50, 65, 70 and 85.</time_frame>
    <description>Vd/F is defined as the apparent volume of distribution of MK-6194 observed in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Peripheral Regulatory T-cells (Tregs) in Whole Blood</measure>
    <time_frame>Baseline and up to 85 days (last study visit)</time_frame>
    <description>The change in the number of peripheral Tregs in whole blood will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Natural Killer (NK) Cells in Whole Blood</measure>
    <time_frame>Baseline and up to 85 days (last study visit)</time_frame>
    <description>The change in the number of NK cells in whole blood will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Number of Conventional T Cells (Tcons) in Whole Blood</measure>
    <time_frame>Baseline and up to 85 days (last study visit)</time_frame>
    <description>The change in the number of Tcons in whole blood will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titer of anti-drug antibody (ADA) of MK-6194</measure>
    <time_frame>Days 1, 29, 57, and 85</time_frame>
    <description>ADA of MK-6194 will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>MK-6194</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be enrolled in sequential cohorts treated with successively higher doses of MK-6194 via subcutaneous injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive MK-6194-matching placebo via subcutaneous injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-6194</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>MK-6194</arm_group_label>
    <other_name>PT101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-6194-matching placebo</intervention_name>
    <description>Subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of UC at least 3 months prior to screening.&#xD;
&#xD;
          -  Mildly to severely active UC.&#xD;
&#xD;
          -  Inadequate response, loss of response, or intolerance to at least 1 prior conventional&#xD;
             therapy, and no more than 2 prior advanced therapies.&#xD;
&#xD;
          -  Participants at risk for colorectal cancer must have a colonoscopy prior to or at&#xD;
             screening as follows:&#xD;
&#xD;
               -  Participants &gt; 50 years of age must have documentation of a colonoscopy within 3&#xD;
                  years of the screening visit to exclude adenomatous polyps. Participants whose&#xD;
                  adenomas have been completely excised at screening are eligible.&#xD;
&#xD;
               -  Participants with extensive colitis for ≥ 8 years, or disease limited to the left&#xD;
                  side of the colon for ≥ 10 years, must either have had a full colonoscopy to&#xD;
                  assess for the presence of dysplasia within 1 year before first administration of&#xD;
                  study drug or a full colonoscopy to assess for the presence of malignancy at the&#xD;
                  screening visit.&#xD;
&#xD;
          -  No evidence of active tuberculosis (TB), latent TB, or inadequately treated TB.&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) and males with female partners of childbearing&#xD;
             potential must utilize highly effective contraceptive methods beginning 4 weeks prior&#xD;
             to first dose of study drug and continue for the duration of the study.&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 35 kg/m^2 inclusive and weight ≥ 50 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with recombinant IL-2 or modified IL-2 therapy, including MK-6194&#xD;
             (PT101).&#xD;
&#xD;
          -  Known sensitivity to MK-6194 (PT101) or its excipients.&#xD;
&#xD;
          -  Known history of hypersensitivity to interleukin-2 (IL-2).&#xD;
&#xD;
          -  Disease limited to the rectum (i.e., within 15 cm of the anal verge).&#xD;
&#xD;
          -  Diagnosis of toxic megacolon.&#xD;
&#xD;
          -  Suspected or known colon stricture or stenosis.&#xD;
&#xD;
          -  Diagnosis of Crohn's disease, or indeterminant colitis.&#xD;
&#xD;
          -  Has severe colitis as evidenced by:&#xD;
&#xD;
               -  Current hospitalization for the treatment of UC&#xD;
&#xD;
               -  Likely to require a colectomy within 12 weeks of baseline in the opinion of the&#xD;
                  Investigator&#xD;
&#xD;
               -  Symptom complex at screening or baseline visits that includes at least 4 of the&#xD;
                  following: diarrhea with ≥ 6 bowel movements/day with macroscopic blood in stool;&#xD;
                  focal severe or rebound abdominal tenderness; persistent fever (≥ 37.5°C);&#xD;
                  tachycardia (&gt; 90 beats/minute); anemia (hemoglobin &lt; 8.5 g/dL).&#xD;
&#xD;
          -  Previously had surgery for UC (e.g., subtotal colectomy with ileo-rectal anastomosis&#xD;
             or colectomy with ileoanal pouch, Koch pouch, or ileostomy) or in the opinion of the&#xD;
             Investigator, likely to require surgery for UC during the study period.&#xD;
&#xD;
          -  History of abnormal thallium stress test or functional cardiac function test.&#xD;
&#xD;
          -  History of significant cardiac, pulmonary, renal, hepatic, or central nervous system&#xD;
             (CNS) impairment.&#xD;
&#xD;
          -  Active clinically significant infection, or any infection requiring hospitalization or&#xD;
             treatment with intravenous anti-infectives within 8 weeks of randomization, or any&#xD;
             infection requiring oral anti-infective therapy within 6 weeks of randomization.&#xD;
&#xD;
          -  History of opportunistic infection.&#xD;
&#xD;
          -  History of symptomatic herpes zoster within 16 weeks of randomization, or any history&#xD;
             of disseminated herpes simplex, disseminated herpes zoster, ophthalmic zoster, or&#xD;
             central nervous system (CNS) zoster.&#xD;
&#xD;
          -  Currently on any chronic systemic (oral or IV) anti-infective therapy for chronic&#xD;
             infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical&#xD;
             mycobacteria).&#xD;
&#xD;
          -  Currently receiving lymphocyte depleting therapy.&#xD;
&#xD;
          -  History of abnormal pulmonary function tests.&#xD;
&#xD;
          -  Participants with organ or tissue allograft.&#xD;
&#xD;
          -  Participants who have HIV infection (positive antibody test) regardless of virologic&#xD;
             status are excluded from the study.&#xD;
&#xD;
          -  Known history of drug or alcohol abuse within 1 year of screening.&#xD;
&#xD;
          -  Malignancy within 5 years of screening, with the exception of adequately treated or&#xD;
             excised non-metastatic basal cell or squamous cell cancer of the skin. Participants&#xD;
             with a malignancy that occurred &gt; 5 years prior to screening are eligible with&#xD;
             documentation of disease-free state since treatment.&#xD;
&#xD;
          -  Immunosuppressive therapy with either cyclosporine A, tacrolimus, or mycophenolate&#xD;
             mofetil within 2 weeks of the Day 1 visit.&#xD;
&#xD;
          -  Exposure to advanced therapy within 5 half-lives of the Day 1 visit, or documentation&#xD;
             of detectable drug during screening.&#xD;
&#xD;
          -  Participants receiving concomitant medications for UC (i.e., oral probiotics,&#xD;
             aminosalicylates, thiopurines, and/or oral corticosteroids) that have not been&#xD;
             administered at stable doses 2 weeks prior to the screening endoscopy or participants&#xD;
             unable or unwilling to maintain stable doses of medications through Week 12 of the&#xD;
             study period. Participants taking oral prednisone or equivalent not greater than 20 mg&#xD;
             per day, or budesonide 9 mg per day are eligible.&#xD;
&#xD;
          -  Participants unable to discontinue topical enemas within 2 weeks prior to endoscopy.&#xD;
&#xD;
          -  Received a live attenuated vaccine &lt; 1 month prior to screening or is planning to&#xD;
             receive a live attenuated vaccine during the study period or within 12 weeks of the&#xD;
             end of participation in the study.&#xD;
&#xD;
          -  Currently enrolled in another investigational device or drug study, or it has been&#xD;
             less than 30 days or 5 half lives since ending another investigational device or drug&#xD;
             study, or receiving another investigational agent.&#xD;
&#xD;
          -  Is pregnant or nursing or is planning to become pregnant during the study.&#xD;
&#xD;
          -  Any uncontrolled or clinically significant concurrent systemic disease other than UC.&#xD;
&#xD;
          -  Any condition or disease that, in the opinion of the Investigator, would pose a risk&#xD;
             to participant safety or interfere with study evaluation, procedures or completion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inland Empire Clinical Trials, LLC ( Site 0102)</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>909-883-2999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research ( Site 0103)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-982-0320</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Star Research Institute ( Site 0101)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>210-271-0606</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine ( Site 0401)</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+373 69 115 584</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Arensia Exploratory Medicine GmbH Ukraine ( Site 0701)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380 673 216 127</phone>
    </contact>
  </location>
  <location_countries>
    <country>Moldova, Republic of</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

